View Financial HealthRenovaCare 배당 및 자사주 매입배당 기준 점검 0/6RenovaCare 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Nov 15RenovaCare, Inc. announced delayed 10-Q filingOn 11/14/2022, RenovaCare, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 12Pomerantz LLP Announces A Class Action Lawsuit Has Been Filed Against RenovaCare, IncPomerantz LLP announces that a class action lawsuit has been filed against RenovaCare, Inc. and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-13930, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired RenovaCare securities between August 14, 2017 and May 28, 2021, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").공시 • Jul 23RenovaCare, Inc Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound HealingRenovaCare, Inc. provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient. Currently, CELLMIST 1, the clinical trial is activated and screening patients at its first burn center. The Company plans to expand its clinical trial to up to four centers in the United States. One site is currently under active negotiation; another candidate site has voluntarily withdrawn from consideration; a fourth clinical site has decided to defer continued negotiations to a later date. The CELLMIST 1 clinical study plans to enroll 14 human subjects between 18 and 65 years old that have partial-thickness, second-degree thermal burn wounds encompassing < 30% total body surface area. Each enrolled subject will be treated within seven days of the burn incident with their own skin cells isolated by the manual CellMist™ System and applied topically onto the burn wound(s) with the Electronic SkinGun™ spray device. Seven follow-up visits over 12 months will evaluate the safety and recovery of each subject.공시 • Jun 08RenovaCare, Inc. Clinical Trial to Start At U.S. Burn CentersRenovaCare, Inc. announced that it is initiating a clinical trial at four burn centers in the United States. This follows the Company’s recent Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). The clinical trial, designated CELLMIST-1, utilizes electronic SkinGun™ spray device and CellMist™ System to render the skin and stem cells uniquely from both the epidermal and dermal layers of the patient’s own skin tissue and then topically spray these cells onto burn wounds to facilitate wound healing. This clinical study will evaluate the safety and feasibility of the Company’s autologous skin stem cell therapy for the treatment of deep second-degree, partial-thickness burn wounds in adults. The CELLMIST-1 clinical study is slated to start enrollment this week at the Burn Center of MedStar Washington Hospital Center (Washington D.C.). In coming weeks, clinical study sites at UMC Burn Center at University Medical Center New Orleans (New Orleans, LA), University of Florida Health Shands Burn Center (Gainesville, FL), and the Regional Burn Center, Tampa General Hospital, University of South Florida Medical Center (Tampa, FL) will open for enrollment.공시 • May 07FDA Grants RenovaCare, Inc. Full Investigational Device Exemption Approval for Safety and Feasibility Clinical TrialRenovaCare, Inc. announced that its investigational device exemption (IDE) application has been granted full approval by the U.S. Food and Drug Administration (FDA). This approval enables the company to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds using skin cells obtained directly from the burn patient. The clinical trial protocol is an open-label, single-arm clinical study that will enroll 14 adult burn subjects with partial-thickness second degree thermal burn wounds. The company expects to conduct the clinical study at four U.S. burn centers over twelve months. Spraying Cells onto Burns and Wounds: to date, over 70 patients with various types of burns have been treated in investigator initiated clinical case studies utilizing the technology underlying the company’s SkinGun™ and CellMist™ System, which the company has developed as a potential alternative to skin grafting and other treatment options, such as in vitro cultured skin epithelial cells that require a specialized and expensive external laboratory. Clinical outcomes of these early experimental studies have been peer-reviewed and published in several medical journals, including Burns and Annals of Plastic Surgery. In late 2019, the company was issued a patent allowing the company’s novel SkinGun™ spray device to spray a variety of tissues and cells, thus opening the door for its potential application in the regeneration of other tissues, beyond skin.공시 • Oct 06Renovacare, Inc. Announces Board ChangesRenovaCare, Inc. announced that Alan L. Rubino, Chief Executive Officer and President, has been elected to the additional role of Chairman of the Board of RenovaCare effective October 1, 2020. Mr. Rubino replaces Harmel S. Rayat as Chairman of the Board, who resigned from the Board and as Chairman on the same date. Mr. Rubino was named President and CEO, and a member of the company’s Board of Directors, in November 2019 to build a highly experienced leadership team with a proven track record to focus the company on its planned transition from a pre-clinical stage to a development/commercial stage entity.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 RCAR 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: RCAR 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장RenovaCare 배당 수익률 vs 시장RCAR의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (RCAR)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (RCAR) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RCAR 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RCAR 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RCAR 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: RCAR 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 16:58종가2026/05/11 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스RenovaCare, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Nov 15RenovaCare, Inc. announced delayed 10-Q filingOn 11/14/2022, RenovaCare, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 12Pomerantz LLP Announces A Class Action Lawsuit Has Been Filed Against RenovaCare, IncPomerantz LLP announces that a class action lawsuit has been filed against RenovaCare, Inc. and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-13930, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired RenovaCare securities between August 14, 2017 and May 28, 2021, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").
공시 • Jul 23RenovaCare, Inc Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound HealingRenovaCare, Inc. provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient. Currently, CELLMIST 1, the clinical trial is activated and screening patients at its first burn center. The Company plans to expand its clinical trial to up to four centers in the United States. One site is currently under active negotiation; another candidate site has voluntarily withdrawn from consideration; a fourth clinical site has decided to defer continued negotiations to a later date. The CELLMIST 1 clinical study plans to enroll 14 human subjects between 18 and 65 years old that have partial-thickness, second-degree thermal burn wounds encompassing < 30% total body surface area. Each enrolled subject will be treated within seven days of the burn incident with their own skin cells isolated by the manual CellMist™ System and applied topically onto the burn wound(s) with the Electronic SkinGun™ spray device. Seven follow-up visits over 12 months will evaluate the safety and recovery of each subject.
공시 • Jun 08RenovaCare, Inc. Clinical Trial to Start At U.S. Burn CentersRenovaCare, Inc. announced that it is initiating a clinical trial at four burn centers in the United States. This follows the Company’s recent Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). The clinical trial, designated CELLMIST-1, utilizes electronic SkinGun™ spray device and CellMist™ System to render the skin and stem cells uniquely from both the epidermal and dermal layers of the patient’s own skin tissue and then topically spray these cells onto burn wounds to facilitate wound healing. This clinical study will evaluate the safety and feasibility of the Company’s autologous skin stem cell therapy for the treatment of deep second-degree, partial-thickness burn wounds in adults. The CELLMIST-1 clinical study is slated to start enrollment this week at the Burn Center of MedStar Washington Hospital Center (Washington D.C.). In coming weeks, clinical study sites at UMC Burn Center at University Medical Center New Orleans (New Orleans, LA), University of Florida Health Shands Burn Center (Gainesville, FL), and the Regional Burn Center, Tampa General Hospital, University of South Florida Medical Center (Tampa, FL) will open for enrollment.
공시 • May 07FDA Grants RenovaCare, Inc. Full Investigational Device Exemption Approval for Safety and Feasibility Clinical TrialRenovaCare, Inc. announced that its investigational device exemption (IDE) application has been granted full approval by the U.S. Food and Drug Administration (FDA). This approval enables the company to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds using skin cells obtained directly from the burn patient. The clinical trial protocol is an open-label, single-arm clinical study that will enroll 14 adult burn subjects with partial-thickness second degree thermal burn wounds. The company expects to conduct the clinical study at four U.S. burn centers over twelve months. Spraying Cells onto Burns and Wounds: to date, over 70 patients with various types of burns have been treated in investigator initiated clinical case studies utilizing the technology underlying the company’s SkinGun™ and CellMist™ System, which the company has developed as a potential alternative to skin grafting and other treatment options, such as in vitro cultured skin epithelial cells that require a specialized and expensive external laboratory. Clinical outcomes of these early experimental studies have been peer-reviewed and published in several medical journals, including Burns and Annals of Plastic Surgery. In late 2019, the company was issued a patent allowing the company’s novel SkinGun™ spray device to spray a variety of tissues and cells, thus opening the door for its potential application in the regeneration of other tissues, beyond skin.
공시 • Oct 06Renovacare, Inc. Announces Board ChangesRenovaCare, Inc. announced that Alan L. Rubino, Chief Executive Officer and President, has been elected to the additional role of Chairman of the Board of RenovaCare effective October 1, 2020. Mr. Rubino replaces Harmel S. Rayat as Chairman of the Board, who resigned from the Board and as Chairman on the same date. Mr. Rubino was named President and CEO, and a member of the company’s Board of Directors, in November 2019 to build a highly experienced leadership team with a proven track record to focus the company on its planned transition from a pre-clinical stage to a development/commercial stage entity.